These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 25749043)

  • 1. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
    Brown DV; Daniel PM; D'Abaco GM; Gogos A; Ng W; Morokoff AP; Mantamadiotis T
    Oncotarget; 2015 Mar; 6(8):6267-80. PubMed ID: 25749043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
    Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
    Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
    Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP
    Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity.
    Brown DV; Filiz G; Daniel PM; Hollande F; Dworkin S; Amiridis S; Kountouri N; Ng W; Morokoff AP; Mantamadiotis T
    PLoS One; 2017; 12(2):e0172791. PubMed ID: 28241049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigating the link between molecular subtypes of glioblastoma, epithelial-mesenchymal transition, and CD133 cell surface protein.
    Zarkoob H; Taube JH; Singh SK; Mani SA; Kohandel M
    PLoS One; 2013; 8(5):e64169. PubMed ID: 23734191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
    Metellus P; Nanni-Metellus I; Delfino C; Colin C; Tchogandjian A; Coulibaly B; Fina F; Loundou A; Barrie M; Chinot O; Ouafik L; Figarella-Branger D
    Ann Surg Oncol; 2011 Oct; 18(10):2937-45. PubMed ID: 21479688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin.
    Lottaz C; Beier D; Meyer K; Kumar P; Hermann A; Schwarz J; Junker M; Oefner PJ; Bogdahn U; Wischhusen J; Spang R; Storch A; Beier CP
    Cancer Res; 2010 Mar; 70(5):2030-40. PubMed ID: 20145155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.
    Liu Q; Nguyen DH; Dong Q; Shitaku P; Chung K; Liu OY; Tso JL; Liu JY; Konkankit V; Cloughesy TF; Mischel PS; Lane TF; Liau LM; Nelson SF; Tso CL
    J Neurooncol; 2009 Aug; 94(1):1-19. PubMed ID: 19468690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD133/CD15 defines distinct cell subpopulations with differential in vitro clonogenic activity and stem cell-related gene expression profile in in vitro propagated glioblastoma multiforme-derived cell line with a PNET-like component.
    Kahlert UD; Bender NO; Maciaczyk D; Bogiel T; Bar EE; Eberhart CG; Nikkhah G; Maciaczyk J
    Folia Neuropathol; 2012; 50(4):357-68. PubMed ID: 23319191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
    Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
    Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneous phenotype of human glioblastoma: in vitro study.
    Denysenko T; Gennero L; Juenemann C; Morra I; Masperi P; Ceroni V; Pragliola A; Ponzetto A; Melcarne A
    Cell Biochem Funct; 2014 Mar; 32(2):164-76. PubMed ID: 23836332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations.
    Yan X; Ma L; Yi D; Yoon JG; Diercks A; Foltz G; Price ND; Hood LE; Tian Q
    Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1591-6. PubMed ID: 21220328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
    Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
    Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD133 is essential for glioblastoma stem cell maintenance.
    Brescia P; Ortensi B; Fornasari L; Levi D; Broggi G; Pelicci G
    Stem Cells; 2013 May; 31(5):857-69. PubMed ID: 23307586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.
    Jing F; Kim HJ; Kim CH; Kim YJ; Lee JH; Kim HR
    Int J Oncol; 2015 Apr; 46(4):1582-8. PubMed ID: 25625240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas.
    Garcia JL; Perez-Caro M; Gomez-Moreta JA; Gonzalez F; Ortiz J; Blanco O; Sancho M; Hernandez-Rivas JM; Gonzalez-Sarmiento R; Sanchez-Martin M
    BMC Cancer; 2010 Aug; 10():454. PubMed ID: 20735813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.
    Liu G; Yuan X; Zeng Z; Tunici P; Ng H; Abdulkadir IR; Lu L; Irvin D; Black KL; Yu JS
    Mol Cancer; 2006 Dec; 5():67. PubMed ID: 17140455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
    Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
    Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.
    Pallini R; Ricci-Vitiani L; Montano N; Mollinari C; Biffoni M; Cenci T; Pierconti F; Martini M; De Maria R; Larocca LM
    Cancer; 2011 Jan; 117(1):162-74. PubMed ID: 20806346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cell signature in glioblastoma: therapeutic development for a moving target.
    Nakano I
    J Neurosurg; 2015 Feb; 122(2):324-30. PubMed ID: 25397368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.